The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B
Source
INSERM, U-773, CRB3, Hôpital Beaujon, AP-HP, Université Paris-Diderot, 100 Boulevard du Général Leclerc, 92110 Clichy, France. tarik.asselah@bjn.aphp.fr
Abstract
Chronic hepatitis B virus (HBV) infection, affecting approximately 350 to 400 million people worldwide, is associated with significant morbidity and mortality. Chronic hepatitis B remains a public health issue despite marked progress in public intervention programs. Individuals with chronic HBV infection have an increased risk for cirrhosis, decompensated liver disease, and hepatocellular carcinoma. The availability of safe and effective vaccines has reduced the burden of diseases. The choice of appropriate pharmacotherapy is critical in altering the course of the infection and reducing the costs associated with the management of chronic hepatitis B.